A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published in the 15 November 2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine; & I.F: 28.054] by Prof. Thistlethwaite PA, Li X and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based therapy for pulmonary arterial hypertension: Berberine inhibits the development of pulmonary arterial hypertension via down regulation of its target gene. Together, pharmacological formulations encompassing “Berberine or its analogues” may be used to treat pulmonary arterial hypertension.
Amount: $ 500
Undisclosed information: How Berberine decreases pulmonary arterial hypertension
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Molecular therapy for pulmonary arterial hypertension: Berberine inhibits the development of pulmonary arterial hypertension via down regulation of its target gene, 24/March/2014, 07.17 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org